Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus apatinib for third-line or later advanced small cell lung cancer
ChiCTR2400087301Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and Rivoceranib in small cell lung cancer (SCLC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400087301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087301.